|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disordersстатья
- Авторы: Himmerich Hubertus, Lewis Yael Doreen, Conti Chiara, Mutwalli Hiba, Karwautz Andreas, Sjögren Jan Magnus, Isaza María Mercedes Uribe, Tyszkiewicz-Nwafor Marta, Aigner Martin, McElroy Susan L., Treasure Janet, Kasper Siegfried, Bailer Ursula, Bulik Cynthia M., Conti Chiara, Zwaan Martina De, Favaro Angela, Fernandez-Aranda Fernando, Fetissov Serguei, Hilbert Anja, Himmerich Hubertus, Hoek Hans Wijbrand, Kan Carol, Karpenko Olga, Karwautz Andreas, Kasper Siegfried, Kaye Walter H., Lewis Yael D., McElroy Susan L., Mitchell James, Monteleone Palmiero, Mörkl Sabrina, Müller Daniel J., Mutwalli Hiba, Nazar Bruno P., Papežová Hana, Sjögren Jan Magnus, Steiger Howard, Stein Daniel, Szabo Christopher P., Tyszkiewicz-Nwafor Marta, Voderholzer Ulrich, Isaza María Mercedes Uribe, Wade Tracey, Wranik Wiesława D., Yoshiuchi Kazuhiro
- Журнал: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
- Год издания: 2023
- Первая страница: 1
- Последняя страница: 64
- DOI: 10.1080/15622975.2023.2179663
- Аннотация: ObjectivesThis 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).MethodsThe WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.ResultsIn anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1). In binge-eating disorder (BED), lisdexamfetamine (LDX; LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1) can be recommended. There is only sparse evidence for the drug treatment of avoidant restrictive food intake disorder (ARFID), pica, and rumination disorder (RD).ConclusionIn BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.
- Добавил в систему: Карпенко Ольга Анатольевна